I'm a little nervous about the trial
Post# of 148179
As a rule I never invest heavily in clinical-stage biotechs, I started piling money into Cytodyn a year ago because leronlimab was proven for HIV and they had just filed the initial part of the BLA so the risk was approval, which seemed like a lock.
I've been cautiously optimistic about the cancer potential but now with this trial for severely ill patients, we're going to either have elation or disappointment very soon. With the hopes of the world and a $1.5 billion, or more, valuation on the line...it's a bit nerve wracking.